Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Evans A: Neuroblastoma a historical perspective. In: Neuroblastoma. Brodeur GM, Sawada T, Tsuchida S, Voute PA (Eds). Elsevier Press, Amsterdam, Holland, 1–7 (2000).
  Google Scholar
• 2  Guillemard V, Saragovi HU: Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets4, 313–326 (2004).
  Google Scholar
• 3  Martin-Zanca D, Hughes SH, Barbacid M: A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature319,743–748 (1986).•• First characterization of the tyrosine kinase receptor (Trk)A oncogene.
  MedlineGoogle Scholar
• 4  Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M: Molecular and biochemical characterisation of the human Trk oncogene. Mol. Cell. Biol.9,24–33 (1989).•• First characterization of TrkA protoncogene.
  MedlineGoogle Scholar
• 5  Oskam R, Coulier F, Ernst M, Martin-Zanca D, Barbacid M: Frequent generation of oncogenes by in vitro recombination of Trk protoncogene sequences. Proc. Natl Acad. Sci. USA85,2964–2968 (1988).
  Medline CASGoogle Scholar
• 6  Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA: RET and NTRK1 proto-oncogenes in human diseases. J. Cell. Physiol. 195(2), 168–186 (2003).
  MedlineGoogle Scholar
• 7  George DJ, Suzuki H, Bova SG, Isaacs JT: Mutational analysis of the TrkA gene in prostate cancer. Prostate36,172–180 (1998).
  Medline CASGoogle Scholar
• 8  Reuther GW, Lambert QT, Caligiuri MA, Der CJ: Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol. Cell. Biol.20,8655–8666 (2000).
  Medline CASGoogle Scholar
• 9  Bibel M, Barde Y-A. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev.14,2919–2937 (2000).
  Medline CASGoogle Scholar
• 10  Nakagawara A: Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett.169,107–114 (2001).• Hypothesis of a potentially critical role for TrkA in neuroblastoma (NB) regression.
  Medline CASGoogle Scholar
• 11  Nakagawara A, Arima M, Azar CG, Scavarla NJ, Brodeur GM: Inverse relationship between trk expression and N-myc amplification in human neuroblastoma. Cancer Res.52,1364–1368 (1992).• First report concerning TrkA expression in NB.
  Medline CASGoogle Scholar
• 12  Nakagawara A, Koger P: Expression and function of Trk and its related genes in human neuroblastoma. In: Neuroblastoma. Brodeur GM, Sawada T, Tsuchida S, Voute PA (Eds). Elsevier Press, Amsterdam, Holland 147–157 (2000).
  Google Scholar
• 13  Matsushima H, Bogenmann E: Nerve growth factor (NGF) induces neuronal differentiation in neuroblastoma cells transfected with the NGF receptor cDNA. Mol. Cell. Biol.10,5015–5020 (1990).
  Medline CASGoogle Scholar
• 14  Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlmen S: Transfection of TrkA into human neuroblastoma cells restores ability to differentiate in response to nerve growth factor. Cell Growth Differ.6,727–736 (1995).
  Medline CASGoogle Scholar
• 15  Lucarelli E, Kaplan D, Thiele CJ: Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells. Eur. J. Cancer33,2068–2070 (1997).
  Medline CASGoogle Scholar
• 16  Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM: Expression of the neurotrophin receptor TrkA downregulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res.62,1802–1808 (2002).• Anti-oncogenic and antiangiogenic effects of TrkA in a model of NB.
  Medline CASGoogle Scholar
• 17  Nakagawara A: Neural crest development and neuroblastoma: the genetic and biological link. Prog. Brain Res.146, 233–242 (2004).
  Medline CASGoogle Scholar
• 18  Tacconelli A, Farina AR, Cappabianca L et al.: TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma. Cancer Cell.6,347–360 (2004).•• First description of the alternative TrkAIII splice variant and its potential role in NB.
  Medline CASGoogle Scholar
• 19  White, PS, Versteeg R: Allelic loss and neuroblastoma suppressor genes. In: Neuroblastoma. Brodeur GM, Sawada T, Tsuchida S, Voute PA (Eds). Elsevier Press, Amsterdam, Holland 57–74 (2000).• Review of genetic alterations associated with NB.
  Google Scholar
• 20  Schwab M. MycN amplification in neuroblastoma. In: Neuroblastoma Brodeur GM, Sawada T, Tsuchida S, Voute PA (Eds). Elsevier Press, Amsterdam, Holland, 75–83 (2000).• Review of MycN association with NB.
  Google Scholar
• 21  Weier H-UG, Rhein AP, Shadravan F, Collins C, Polikoff D: Rapid physical mapping of the human protoncogene (NTRK1) to human chromosome 1q21–q22 by P1 clone selection, fluorescence in situ hybridisation (FISH), and computer-assisted microscopy. Genomics26,390–393 (1995).
  Medline CASGoogle Scholar
• 22  Greco A, Villa R, Pierotti MA: Genomic organisation of the human NTRK1 gene. Oncogene13,2463–2466 (1996).•• First description of human TrkA genomic organization.
  Medline CASGoogle Scholar
• 23  Barker PA, Lomen-Hoerth C, Gensch EM, Meakin SO, Glass DJ, Shooter EM. Tissue specific alternative splicing generates two isoforms of the TrkA receptor. J. Biol. Chem.268,15150–15157 (1993).• First report of alternative TrkAI and AII splice variants.
  Medline CASGoogle Scholar
• 24  Clary DO, Reichardt LF: An alternative spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. Proc. Natl Acad. Sci. USA11133–11137 (1994).
  MedlineGoogle Scholar
• 25  Zaccaro MC, Ivanisevic L, Perez P, Meakin SO, Saragovi UH: P75 co-receptors regulate ligand-independent and ligand-dependent Trk receptor activation, in part by altering Trk-docking domains. J. Biol. Chem.276,31023–31029 (2002).
  MedlineGoogle Scholar
• 26  Nykjaer A, Willnow TE, Petersen CM: p75NTR-live or let die. Curr. Opin. Neurobiol.15,49–57 (2005).• Review of the p75 neurotrophin receptor and interaction with TrkA.
  Medline CASGoogle Scholar
• 27  Kaplan DR, Miller FD: Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol.10,381–391 (2000).
  Medline CASGoogle Scholar
• 28  Patapoutian A, Reichard LF: Trk receptors: mediators of neurotrophin action Curr. Opin. Neurobiol.11,272–280 (2001).
  Medline CASGoogle Scholar
• 29  Windisch JM, Marksteiner R, Schneider R: Nerve growth factor binding site on TrkA mapped to a single 24-amino acid-rich leucine-rich motif. J. Biol. Chem.270,28133–28136 (1995).
  Medline CASGoogle Scholar
• 30  Holden PH, Asopa V, Robertson AG et al.: Immunoglobulin-like domains define the nerve growth factor binding site for the TrkA receptor. Nature Biotechnol.15,668–672 (1997).
  Medline CASGoogle Scholar
• 31  Arevalo JC, Conde B, Hempstead BL, Chao MV, Matrin-Zanca D, Perez P: TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol. Cell. Biol.20,5908–5916 (2000).•• Demonstration of the importance of TrkA extracellular immunoglobulin (Ig)G domains in receptor function and prevention of ligand independent oncogenic activation.
  Medline CASGoogle Scholar
• 32  Peng X, Greene LA, Kaplan DR, Stephens RM: Deletion of a conserved juxtamembrane sequence in Trk abolishes NGF-promoted neuritogenesis. Neuron15,395–406 (1995).
  Medline CASGoogle Scholar
• 33  Monshipouri M, Jiang H, Lazarovici P: NGF stimulation of erk phosphorylation is impaired by a point mutation in the transmembrane domain of trkA receptor. J. Mol Neurosci.14,69–76 (2000).
  Medline CASGoogle Scholar
• 34  Kaplan DR, Martin-Zanca D, Parada LF: Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature350,358–360 (1991).•• First demonstration of TrkA as a receptor tyrosine kinase.
  Google Scholar
• 35  Meakin SO, Shooter EM: Tyrosine kinase activity coupled to the high-affinity nerve growth factor-receptor complex. Proc. Natl Acad. Sci. USA88,5862–5866 (1991).
  Medline CASGoogle Scholar
• 36  Mischel PS, Umbach JA, Eskandari S, Smith SG, Gundersen CB, Zampighi GA: Nerve growth factor signals via pre-existing TrkA receptor oligomers. Biophys. J.83,968–976 (2002).•• Interesting article suggesting TrkA oligomerization in the absence of ligand.
  Medline CASGoogle Scholar
• 37  Paratcha G, Ibanez CF: Lipid rafts and the control of neurotrophic signalling in the nervous system: variations on a theme. Curr. Opin. Neurobiol.12,542–549 (2002).• Role of lipid rafts in neurotrophin signal transduction.
  Medline CASGoogle Scholar
• 38  Marsh HN, Dubreuil CI, Quevedo C et al.: SHP-1 negatively regulates Neuronal survival by functioning as a TrkA phosphatase. J.Cell Biol.163,999–1010 (2003).
  CASGoogle Scholar
• 39  Watson FL, Porcionatto MA, Bhattacharyya A, Stiles C, Segal RA: TrkA glycosylation regulates localisation and activity. J. Neurobiol.39,323–336 (1999).• Demonstration that TrkA extracellular domain N-glycosylation regulates membrane localization and ligand-independent activation without RAS/mitogen-activated protein kinase (MAPK) activation.
  Medline CASGoogle Scholar
• 40  Coulier F, Kumar R, Ernst M, Klein R, Martin-Zanca D, Barbacid M: Human Trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tryrosine kinase domain. Mol. Cell. Biol.10,4202–4210 (1990).
  Medline CASGoogle Scholar
• 41  Borello MG, Pelicci G, Arighi E et al.: The oncogenic versions of Ret and Trk tyrosine kinases bind Shc and Grb-2 adapter proteins. Oncogene.9,1661–1668 (1994).
  MedlineGoogle Scholar
• 42  Meakin SO, MacDonald JIS, Gryz EA, Kubu CJ, Verdi JM: The signalling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model discriminating between proliferation and differentiation. J. Biol. Chem.274,9861–9870 (1999).
  Medline CASGoogle Scholar
• 43  Arevalo JC, Conde B, Hempstead BI, Chao MV, Martin-Zanca D, Perez P: A novel mutation within the extra cellular domain of TrkA causes constitutive receptor activation. Oncogene20,1229–1234 (2001).
  Medline CASGoogle Scholar
• 44  Scaruffi P, Cusano R, Dagnino M, Tonini GP: Detection of DNA polymorphisms and point mutations of high affinity nerve growth factor receptor (TrkA) in human neuroblastoma. Int. J. Oncol.14,935–938 (1999).
  Medline CASGoogle Scholar
• 45  Shimada H, Nakagawara A, Peters J, Wang H, Wakamatsu PK, Lukens JN et al.: TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer101,1873–1881 (2004).• TrkA expression and its relationship to prognosis in neuroblastoma with particular reference to MycN amplification and histologic status.
  Medline CASGoogle Scholar
• 46  Azar CG, Scavarda NJ, Reynolds CP, Brodeur GM: Multiple defects of the nerve growth factor receptor in human neuroblastomas. Cell Growth Differ.1,421–428 (1990).
  Medline CASGoogle Scholar
• 47  Sugimoto T, Kuroda H, Horii Y, Moritake H, Tanaka T, Hattori: Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells. Jpn J. Cancer Res.92,152–160 (2001).
  Medline CASGoogle Scholar
• 48  Eggert A, Ikegaki N, Liu X et al.: Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene.19,2043–2051 (2000).
  Medline CASGoogle Scholar
• 49  Hallberg B, Ashcroft M, Loeb DM, Kaplan DR: Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase. Oncogene.17,691–697 (1998).
  Medline CASGoogle Scholar
• 50  Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M: Regulation of Raf–Akt Cross-talk. J. Biol. Chem.277,31,099–31,106 (2002).
  CASGoogle Scholar
• 51  Tagliabue E, Ghirelli C, Lombardi L et al.: Production of a monoclonal antibody directed against the high affinity nerve growth factor receptor. Int. J. Biomarkers14,68–72 (1999).
  Medline CASGoogle Scholar
• 52  Covaceuszach S, Cattaneo A, Lamba D: Neutralisation of NGF-TrkA receptor interaction by the novel antagonistic antiTrkA monoclonal antibody MNAC13: a structural insight. Proteins58,717–727 (2005).
  Medline CASGoogle Scholar
• 53  Urfer R, Tsoulfas P, O'Connell L, Shelton DL, Parada LF, Presta LG: An immunoglobulin-like domain determines the specificity of neurotrophin receptors. EMBO J.14,2795–2805 (1995).
  Medline CASGoogle Scholar
• 54  Harris AL: Hypoxia-a key regulatory factor in tumor growth. Nature Rev. Cancer2,38–47 (2002).•• Review on hypoxia effects upon tumor progression.
  Medline CASGoogle Scholar
• 55  Jogi A, Ora I, Nilsson H et al.: Hypoxia alters gene expression in human neuroblastoma cells toward an immature neural crest-like phenotype. Proc. Natl Acad. Sci. USA99,7021–7026 (2002).•• Suggests that hypoxia promotes a more aggressive NB phenotype.
  Medline CASGoogle Scholar
• 56  Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT: Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl Acad. Sci. USA95,11715–11720 (1998).
  Medline CASGoogle Scholar
• 57  Salnikow K, Weicheng S, Blagosklonny MV, Costa M: Carcinogenic metals induce hypoxia-inducible factor stimulating transcription by reactive oxygen species-independent mechanism. Cancer Res.60,3375–3378 (2000).
  Medline CASGoogle Scholar
• 58  Asosingh K, De Raeve H, de Ridder M et al.: Role of the hypoxic bone marrow microenvironment in 5TMM murine myeloma tumor progression. Haematologica90,810–817 (2005)•• Suggests that the hypoxic bone marrow environment may promote tumor progression.
  Medline CASGoogle Scholar